VBI Vaccines Shares Unaffected Following Seeking Alpha Blogpost 'Analysis Of SCI-B-VAC's Overwhelming Phase III Clinical Data Suggests VBI Vaccines' Share Price Is Materially Undervalued'
Benzinga Newsdesk